Mylan Pharmaceuticals Private Limited (a subsidiary of Mylan N.V.) has launched Velpatasvir 100 mg/Sofosbuvir 400 mg tablets under the brand name MyHep All in India. MyHep All is a fixed-dose combination tablet indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults, including all six major HCV genotypes. A Velpatasvir 100 mg /Sofosbuvir 400 mg combination product is currently sold by Gilead Sciences in other markets under the brand name EPCLUSA.

The MyHep All launch follows Mylan's successful launch of MyHep LVIR (Ledipasvir/Sofosbuvir combination) in India in January 2016. Mylan has the nonexclusive right to manufacture and distribute Velpatasvir/Sofosbuvir in approximately 100 developing countries via a license agreement from Gilead Sciences.

10 Diagnostic Imaging Trends for 2018


Digital version